Global Infectious Disease Diagnostics Market is valued at USD 29.41 Billion in 2021 and is expected to reach USD 47.70 Billion by 2028 with a CAGR of 7.1% over the forecast period.
Global Infectious Disease Diagnostics Market Size, Trends, Competitive, Historical & Forecast Analysis to 2022-2028, Increasing prevalence of infectious diseases, a growing number of funding for research on infectious disease diagnostics, rising demand for point of care diagnostics test as well as an increasing number of medical laboratories for infectious disease diagnostics testing are driving the growth of Global Infectious Disease Diagnostics market.
Infectious-disease diagnostics is the process by which the causative agent of an infectious disease is recognized and often characterized. It can be based solely on clinical performance or more rigorous diagnostic tests, such as culturing of the infectious agent, microscopy, biochemical screens, and molecular methods. Infectious diseases are detected by detection of a bacterium, virus, fungus, protozoan, or helminth in a patient with a compatible clinical illness. The methods of detection include cultivation of bacteria and fungi on the growing medium, isolation of viruses in cell culture, and identification of the agent biochemically, antigenically, or genetically. Infectious diseases can also be recognized by the detection of a specific immune response, usually antibodies that develop during the course of illness.
Covid-19 has shown a positive impact on the growth of the infectious disease diagnostics market. The outbreak of the Covid-19 pandemic has impacted the Covid-19 is an infectious disease caused by the most recently exposed novel coronavirus. Largely unidentified before the outbreak began in Wuhan (China) in December 2019, Covid-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The Covid-19 pandemic negatively affected the overall sales of most of the companies but had a positive impact on the infectious disease diagnostics market since of the use of infectious disease diagnostic methods for Covid-19 testing.
The infectious disease diagnostics market is segmented based on product, type of testing, technology, disease type, end-user and region & country level. Based on product, the market is classified into reagents, kits, and consumables, instruments and software & services. Based on type of testing, the global infectious disease diagnostics market is classified into laboratory testing and POC testing. Based on technology, the market is classified into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays and other technologies. Based on disease type, the global infectious disease diagnostics market is classified into COVID-19, HIV, HAIs, Hepatitis, CT/NG, HPV, TB, Influenza and other infectious diseases. Based on end-user, the market is classified into diagnostic laboratories, hospitals & clinics, academic research institutes and other end users.
The regions covered in this infectious disease diagnostics market report are Asia-Pacific, North America, Europe, and the Rest of the World. Based on a country level, the market of infectious disease diagnostics is subdivided into the U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
On December 15th, 2021; Roche announced the launch of the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardised performance and efficiencies across low, medium and high volume molecular laboratory testing needs.
On October 11th, 2021; Aegis Sciences Corporation expanded its molecular testing capabilities to rapidly identify pathogens in the respiratory and urogenital health spaces. With Aegis Infectious Disease Testing, providers will have access to: Clinically relevant tests for a wide variety of pathogens and condition, diversity in specimen collection options, 24-hour turnaround time, semi-quantitative reporting available where clinically appropriate and clear, reliable, and actionable results. The testing menu includes customizable order options for the most common pathogens that cause respiratory tract infections (RTIs), genital health/sexually transmitted infections (STIs), gastrointestinal infections (GIs) and urinary tract infections (UTIs).
On March 16th, 2021; Roche launched the cobas SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found in variants that originated in the UK, South Africa, and Brazil. This research use only laboratory test can be used to help scientists track mutation prevalence and to assess any potential impact on diagnostics, vaccines and therapeutics, providing crucial insight for healthcare systems in making appropriate measures to combat Covid-19.
On March 27th, 2020-; Abbott announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.
The rising cases of Covid-19 and growing prevalence of infectious diseases are some of the major factors driving the growth of global infectious disease diagnostics market. For example; according to the WHO, on January 12th, 2022, there have been 47,003,518 active cases of Covid-19 worldwide. Moreover, according to the European Centre for Disease Prevention and Control, chikungunya cases in 2021, 225 696 cases were reported, the majority from Brazil (127 487), India (91 477).
In addition, the rising focus of market players and an increasing number of product launches are also supplementing the market growth. Furthermore, recently in 2021, Roche announced the launch of the cobas SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found invariants that originated in the UK, South Africa, and Brazil as well as in 2020 Abbott announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), conveying positive results in as five minutes and negative results in 13 minutes. Infectious diseases similar to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Ebola, chikungunya, avian flu, swine flu, and Zika has opened door for their early diagnosis & prevention. In this diagnostics test shows result with minimum time periods which is fostering the growth of global infectious disease diagnostics market. Furthermore, rising number of medical laboratories for infectious disease diagnostics is also fostering the market growth.
However, high price associated with diagnostics instruments and deficiency of skill techniques may hinder the growth of the infectious disease diagnostics market. Despite that, technological advancements in diagnostic instruments and increasing awareness regarding early diagnosis may create more growth opportunities for the market players.
Geographically, North America is expected to account for the leading share of the global infectious disease diagnostics market owing to the highly developed healthcare organization in the US and Canada, the presence of numerous leading national clinical laboratories, and the easy availability to technologically advanced instruments in this region. In addition, rising cases of Covid-19 is also fostering market growth in this region. For example; as of January 10th, 2022; according to the Worldometer; total number of active cases of Covid are 19,885,128 in the U.S.
The factors driving the growth of Europe's infectious disease diagnostics market are government funds to cure the infectious diseases and rising cases of infectious diseases. According to the, European Institute of Innovation & Technology (EIT) Health had declared funds of almost $7.69 million (7 million euros) in the fight against Covid-19, which be dedicated to 15 health innovation projects across Europe. The project focuses on direct and impactful solutions for better tools in navigating the pandemic.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 29.41 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 47.70 Billion|
|Tables, Charts & Figures:||175|
|Infectious Disease Diagnostics Companies||Abbott Laboratories, Roche Diagnostics Ltd., bioMérieux SA, Thermo Fisher Scientific Inc., Danaher Corporation, Chembio Diagnostic Systems, Inc., Seegene Inc., Co-Diagnostics, Inc., ELITechGroup, Epitope Diagnostics, Inc., Trivitron Healthcare, Meril Life Sciences Pvt. Ltd., InBios International, Inc., ABACUS Diagnostica Oy, others|
|Segments Covered||By Product, By Type of Testing, By Technology, By Disease Type, By End User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
Middle East and Africa